These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 28050603)

  • 1. New open conformation of SMYD3 implicates conformational selection and allostery.
    Spellmon N; Sun X; Xue W; Holcomb J; Chakravarthy S; Shang W; Edwards B; Sirinupong N; Li C; Yang Z
    AIMS Biophys; 2017; 4(1):1-18. PubMed ID: 28050603
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Smyd3 open & closed lock mechanism for substrate recruitment: The hinge motion of C-terminal domain inferred from μ-second molecular dynamics simulations.
    Chandramouli B; Silvestri V; Scarno M; Ottini L; Chillemi G
    Biochim Biophys Acta; 2016 Jul; 1860(7):1466-74. PubMed ID: 27085704
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanism of the Conformational Change of the Protein Methyltransferase SMYD3: A Molecular Dynamics Simulation Study.
    Sun J; Li Z; Yang N
    Int J Mol Sci; 2021 Jul; 22(13):. PubMed ID: 34281237
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Conformational Dynamics of Lysine Methyltransferase Smyd2. Insights into the Different Substrate Crevice Characteristics of Smyd2 and Smyd3.
    Chandramouli B; Chillemi G
    J Chem Inf Model; 2016 Dec; 56(12):2467-2475. PubMed ID: 27959541
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structural Basis for Substrate Preference of SMYD3, a SET Domain-containing Protein Lysine Methyltransferase.
    Fu W; Liu N; Qiao Q; Wang M; Min J; Zhu B; Xu RM; Yang N
    J Biol Chem; 2016 Apr; 291(17):9173-80. PubMed ID: 26929412
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structural insights into the autoinhibition and posttranslational activation of histone methyltransferase SmyD3.
    Sirinupong N; Brunzelle J; Doko E; Yang Z
    J Mol Biol; 2011 Feb; 406(1):149-59. PubMed ID: 21167177
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is MYND Domain-Mediated Assembly of SMYD3 Complexes Involved in Calcium Dependent Signaling?
    Zhang Y; Li C; Yang Z
    Front Mol Biosci; 2019; 6():121. PubMed ID: 31737645
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structural and biochemical studies of human lysine methyltransferase Smyd3 reveal the important functional roles of its post-SET and TPR domains and the regulation of its activity by DNA binding.
    Xu S; Wu J; Sun B; Zhong C; Ding J
    Nucleic Acids Res; 2011 May; 39(10):4438-49. PubMed ID: 21266482
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SMYD3 stimulates EZR and LOXL2 transcription to enhance proliferation, migration, and invasion in esophageal squamous cell carcinoma.
    Zhu Y; Zhu MX; Zhang XD; Xu XE; Wu ZY; Liao LD; Li LY; Xie YM; Wu JY; Zou HY; Xie JJ; Li EM; Xu LY
    Hum Pathol; 2016 Jun; 52():153-63. PubMed ID: 26980013
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exploration of the Substrate Preference of Lysine Methyltransferase SMYD3 by Molecular Dynamics Simulations.
    Sun J; Shi F; Yang N
    ACS Omega; 2019 Nov; 4(22):19573-19581. PubMed ID: 31788587
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Histone methyltransferase SMYD3 promotes MRTF-A-mediated transactivation of MYL9 and migration of MCF-7 breast cancer cells.
    Luo XG; Zhang CL; Zhao WW; Liu ZP; Liu L; Mu A; Guo S; Wang N; Zhou H; Zhang TC
    Cancer Lett; 2014 Mar; 344(1):129-137. PubMed ID: 24189459
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overexpression of SMYD3 in Ovarian Cancer is Associated with Ovarian Cancer Proliferation and Apoptosis via Methylating H3K4 and H4K20.
    Jiang Y; Lyu T; Che X; Jia N; Li Q; Feng W
    J Cancer; 2019; 10(17):4072-4084. PubMed ID: 31417652
    [No Abstract]   [Full Text] [Related]  

  • 13. Discovery of the SMYD3 Inhibitor BAY-6035 Using Thermal Shift Assay (TSA)-Based High-Throughput Screening.
    Gradl S; Steuber H; Weiske J; Szewczyk MM; Schmees N; Siegel S; Stoeckigt D; Christ CD; Li F; Organ S; Abbey M; Kennedy S; Chau I; Trush V; Barsyte-Lovejoy D; Brown PJ; Vedadi M; Arrowsmith C; Husemann M; Badock V; Bauser M; Haegebarth A; Hartung IV; Stresemann C
    SLAS Discov; 2021 Sep; 26(8):947-960. PubMed ID: 34154424
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Unveiling the Biochemistry of the Epigenetic Regulator SMYD3.
    Fabini E; Talibov VO; Mihalic F; Naldi M; Bartolini M; Bertucci C; Del Rio A; Danielson UH
    Biochemistry; 2019 Sep; 58(35):3634-3645. PubMed ID: 31389685
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SET and MYND domain-containing protein 3 decreases sensitivity to dexamethasone and stimulates cell adhesion and migration in NIH3T3 cells.
    Luo XG; Ding Y; Zhou QF; Ye L; Wang SZ; Xi T
    J Biosci Bioeng; 2007 May; 103(5):444-50. PubMed ID: 17609160
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutical potential of deregulated lysine methyltransferase SMYD3 as a safe target for novel anticancer agents.
    Rajajeyabalachandran G; Kumar S; Murugesan T; Ekambaram S; Padmavathy R; Jegatheesan SK; Mullangi R; Rajagopal S
    Expert Opin Ther Targets; 2017 Feb; 21(2):145-157. PubMed ID: 28019723
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SMYD3 promotes epithelial ovarian cancer metastasis by downregulating p53 protein stability and promoting p53 ubiquitination.
    Zhang L; Jin Y; Yang H; Li Y; Wang C; Shi Y; Wang Y
    Carcinogenesis; 2019 Dec; 40(12):1492-1503. PubMed ID: 31002112
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SMYD3 promotes implant metastasis of ovarian cancer via H3K4 trimethylation of integrin promoters.
    Lyu T; Jiang Y; Jia N; Che X; Li Q; Yu Y; Hua K; Bast RC; Feng W
    Int J Cancer; 2020 Mar; 146(6):1553-1567. PubMed ID: 31503345
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Histone methyltransferase SMYD3 regulates the expression of transcriptional factors during bovine oocyte maturation and early embryonic development.
    Bai H; Li Y; Gao H; Dong Y; Han P; Yu H
    Cytotechnology; 2016 Aug; 68(4):849-59. PubMed ID: 25563599
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel small molecule ZYZ384 targeting SMYD3 for hepatocellular carcinoma via reducing H3K4 trimethylation of the Rac1 promoter.
    Ding Q; Cai J; Jin L; Hu W; Song W; Rose P; Tang Z; Zhan Y; Bao L; Lei W; Zhu YZ
    MedComm (2020); 2024 Oct; 5(10):e711. PubMed ID: 39286779
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.